Dividends & Income
To screen ETFs by asset class, performance, yield and more, check out the
This user currently has no profile.
Over 15 years of experience in biotech, Big Pharma, and academic experience. I hold a Ph.D. in chemistry with an extensive background in pharmacology, drug discovery and development, as well as evaluation and diligence for licensing and acquisition opportunities.
PE Fund Analyst.
Stocks - long, Tech stocks
Currently, there is no company profile for Pharmageddon.
Currently, there are no blog details for Pharmageddon.
Currently, there are no book details for Pharmageddon.
The author makes the assump...
Arena Is Still A Great Short
The problem for Vivus isn't...
Vivus Gets Restrictions Loosened
Star may have a useful comp...
Breaking News For Star Scientific: Anatabine Is...
Interesting how every major...
Is Acadia A Buy After Jumping Over 50%?
MTX is a cheap generic. It'...
Bio Run-Ups: What To Expect In The Next Few Months
Xignite quote data
© 2015 Seeking Alpha